Eastern Food Allergy & Comorbidity Conference 2025 (EFACC)

Palm Beach, FL US
January 9, 2025 to January 12, 2025

The 2025 EFACC activity will provide conference attendees with knowledge regarding novel food allergy developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology, particularly as it relates to food allergies and associated allergic comorbidities. In addition to a didactic review of relevant guidelines and recent clinical studies, the format will incorporate problem-based learning (PBL), uniquely designed to interface with lectures in context to the core learning objectives relevant to the cases. By means of active discussion, learners will be challenged to formulate and justify medical decision-making concerning diagnostic and treatment strategies for patients food allergy and comorbid allergic diseases. Topics of discussion will include food allergy prevention, food allergy immunotherapy, asthma, atopic dermatitis, eosinophilic esophagitis and shared decision making.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Eastern Food Allergy & Comorbidity Conference (EFACC)  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 16.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 16.25 contact hours. 

Commercial Support
No commercial support was received for this activity.

Target Audience

Practicing allergists
Primary care physicians
Allied healthcare professionals

Learning Objectives

At the conclusion of this Activity learners should be able to…
1. Initiate an appropriate treatment strategy for eosinophilic esophagitis. 
2. Discuss the risks and benefits of various forms of food immunotherapy. 
3. Manage intermittent, mild/moderate, and severe persistent asthma as comorbidities of food allergy.
4. Manage atopic dermatitis as a comorbidity of food allergy. 
5. Incorporate shared decision-making into food allergy management.
6. Optimize anaphylaxis preparedness and treatment in food allergy.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 16.25 AMA PRA Category 1 Credit™
  • 16.25 Attendance
  • 16.25 CBRN
Course opens: 
01/09/2025
Course expires: 
12/31/2026
Event starts: 
01/09/2025 - 3:30pm CST
Event ends: 
01/12/2025 - 10:30am CST
Rating: 
0

Eastern Food Allergy & Comorbidity Conference Meeting Program
January 9 -12, 2025
The Breakers, Palm Beach FL

Thursday, January 9, 2025

Moderator:    Katherine Anagnostou, MD

3:30-4:00    Food allergy has come a long way: Where should it go from here? – Sami Bahna, MD

4:00-4:30    Management options for EoE: Use of biologics – Peter Capucilli, MD

4:30-5:00    Atopic dermatitis management: Key messages from the new practice parameter update – Peck Ong, MD

5:00-5:15    Panel Discussion: Q & A

5:15-5:45    Journal of Food Allergy: Year-in-review workshop – Katherine Anagnostou, MD

5:45-6:15    How do food allergies and immune deficiencies interact? – Joseph Bellanti, MD

6:15-6:30     Panel Discussion: Q & A

Adjourn

Friday, January 10, 2025

Moderator:    Katherine Anagnostou, MD

7:45-8:15    Managing food allergy in 2025: An evolving landscape – Rima Rachid, MD

8:15-9:30    PBL: A five-year-old with milk, egg and peanut allergy, SAR and intermittent asthma
Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD, Dana Wallace, MD

9:30-10:15    Coffee Break: Visit exhibits and posters 

10:15-10:45    Oral immunotherapy in food allergy – Anna Nowak-Wegrzyn, MD

10:45-11:15    Omalizumab for food allergy: Risks and benefits – Shahzad Mustafa, MD

11:15-11:45    Sublingual immunotherapy for food allergy: How and when to use – Edwin Kim, MD

11:45-12:15    Epicutaneous immunotherapy for peanut allergy: An update – Matthew Greenhawt, MD

12:15-12:30    Panel Discussion: Q & A

Moderator:    Robert Settipane, MD

1:25-2:50    Workshops

Shared decision-making in food allergy therapies
Matthew Greenhawt, MD and Katherine Anagnostou, MD

Communicating new therapies to patients and providing reliable resources
Julie Wang, MD and Doug Mack, MD

2:50-3:00    Panel Discussion: Q & A

Adjourn

Saturday, January 11, 2025

Moderator:    Russell Settipane, MD

7:45-8:15    Anaphylaxis Practice Parameter: Key messages – Jay Lieberman, MD

8:15-9:30    PBL: A 15-year-old with asthma tree nut allergy experiencing multiple episodes of anaphylaxis
Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD Marcus Shaker, MD

9:30-10:15    Coffee Break: Visit exhibits and posters

10:15-10:45    Anaphylaxis Update 1: When to activate EMS – Marcus Shaker, MD

10:45-11:15    Anaphylaxis update 2: Epinephrine devices for food-allergic individuals: Who, how many and when to use – Jay Lieberman, MD

11:15-11:45    Anaphylaxis update 3: How to prepare schools and the community to manage anaphylaxis – Julie Wang, MD

11:45-12:15    How to manage asthma in a food-allergic patient: A practical approach – Doug Mack, MD

12:15-12:30    Panel Discussion: Q & A

Moderator:    William Corrao, MD

1:25-1: 55    Yellow zone management for intermittent and mild/moderate persistent asthma – Shahzad Mustafa, MD

1:55-2:20    Biologics in asthma management – Rima Rachid, MD

2:20-2:50    The use of thresholds in food allergy management – Marcus Shaker, MD

2:50-3:00    Panel Discussion: Q & A

Adjourn

Sunday, January 12, 2025

Moderator:    William Greisner, MD

8:15-8:45    Management options for EoE: Diet or steroids? – Emily McGowan, MD

8:45-9:15    Challenging cases in FPIES management – Anna Nowak-Wegrzyn, MD

9:15-9:45    Selecting patients for food allergy therapy – Katherine Anagnostou, MD

9:45-10:15    Workshop: Preparing food allergic patients for college: Practical advice and resources – Ruchi Gupta, MD

10:15 -10:30     Panel Discussion: Q & A

Adjourn

The Breakers
1 South County Road
Palm Beach, FL 33480
United States

All identified relevant financial relationships with ineligible companies have been mitigated.

Katherine Anagnostou, MD – Speaker, Planner, Moderator
Advisor: Novartis, Genentech, ARS, Bryn
Speaker: Genentech, ARS 
Researcher: Novartis

Don Bukstein, MD - Speaker
Speaker: Regeneron
Advisor: Amphaster

Ray Davis, MD - Speaker
Consultant: Sanofi, Regeneron, Grifols, Kalvista, AstraZeneca

Matthew Greenhawt, MD - Speaker
Speaker: Genentech 
Consultant: Aquestive
Advisor: Nutricia, DBV, Novartis, Aquestive, Prota, Allergy Therapeutics, ALK-Abello, AstraZeneca, Bryn, Genentech, Takeda, Grifols

William Greisner, III, MD – Planner, Moderator
Researcher: Allakos, AstraZeneca, GSK, Eli Lilly

Ruchi Gupta, MD - Speaker
Researcher: Novartis, Genentech
Consultant: Novartis, Genentech, OWYN, Kaleo, Aquestive Therapeutics, Bryn Pharma

Edwin Kim MD - Speaker
Advisor: ALK, Cellergy Pharm, Ukko
Consultant: Genentech, Hanimune Therapeutics, Novartis, Phylaxis Bioscience, Revolo Biotherapeutics, Allakos, DBV Technologies 

Jay Lieberman, MD - Speaker
Advisor: AbbVie, Aquestive, ARS, Bryn, Celldex, Genentech, Novartis, Theravia
Consultant: AbbVie, Novartis, Aquestive, ARS, Bryn, Celldex, Genentech, Novartis, Theravia
Researcher: DBV

Doug Mack, MD - Speaker
Researcher: ALK-Abello, DBV, AstraZeneca, Arcutis, Dermavant, Sanofi, Leo 
Advisor: DBV, Bausch Health, ALK Abello, Covis, Trudell, GSK
Speaker: DBV, ALK-Abello, Bausch Health, Covis, Trudell, GSK

S. Shahzad Mustafa, MD – Speaker
Speaker: Genentech, Regeneron/Sanofi, GSK, AstraZeneca, CSL Behring

Anna Nowak-Wegrzyn, MD - Speaker
Speaker: Nestle Sciences, Danone Nutricia, Thermofisher Scientific, Genentech
Consultant: Nestle Sciences, Danone Nutricia
Researcher: DBV, Siolta Therapeutics

Peck Ong, MD – Speaker
Advisor: Dermavant, Amgen
Researcher: Regeneron

Rima Rachid, MD - Speaker
Researcher: Novartis, Siolta Therapeutics
Consultant: Novartis

Russell Settipane, MD – Speaker, Moderator, Planner, Reviewer
Speaker: AbbVie, Amgen, AstraZeneca, BioCryst, GSK, Genentech, Grifols, Pharming, Regeneron, Sanofi, Takeda
Advisor: AbbVie, Pfizer, AstraZeneca, BioCryst, GSK, DBV, Kalvista, Pharming
Independent Contractor: AstraZeneca, BioCryst, GSK, Regeneron, DBV, Genentech, Takeda

Julie Wang, MD - Speaker
Royalties: UpToDate
Researcher: DBV, Siolta

Dana Wallace, MD – Speaker
Consultant: Genentech, ARS, Bryn, Grifols

The following have no relevant financial relationships with ineligible companies:

Sam Bahna, MD - Speaker
Joseph Bellanti, MD – Speaker
Peter Capucilli, MD – Speaker 
William Corrao, MD – Moderator, Planner
Ginny Loiselle - Coordinator
Katelyn Loiselle, BSN, RN – Planner
Emily McGowan, MD - Speaker
Robert Settipane, MD – Planner, Moderator
Marcus Shaker, MD - Speaker

 

Available Credit

  • 16.25 AMA PRA Category 1 Credit™
  • 16.25 Attendance
  • 16.25 CBRN
Please login or create an account to take this course.